A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients with Solid Tumors (INVOKE)
NCT 06789172 Brief Summary The purpose of this study is to investigate…
Read more arrow_forwardNCT 06789172 Brief Summary The purpose of this study is to investigate…
Read more arrow_forwardNCT 06956690 Brief Summary This study is a Phase 1/2, first-in-human, open-label,…
Read more arrow_forwardNCT 03746431 Brief Summary This is a first-in-human Phase 1/2, non-randomized, multi-centre,…
Read more arrow_forwardNCT 05914116 Brief Summary This is a dose-escalation and dose-expansion Phase 1/2a…
Read more arrow_forwardACTRN 12624001138572 Brief Summary This study aims to determine the safety, tolerability…
Read more arrow_forwardNCT 05304377 Brief Summary The purpose of this study is to evaluate…
Read more arrow_forwardACTRN 12622000993796 Brief Summary AXA-042 functions through a multi-cellular mechanism to re-engage…
Read more arrow_forwardACTRN 12623001072606 Brief Summary This study aims to assess the effect of…
Read more arrow_forwardNCT 04973605 Brief Summary Study consists of two parts, a part 1…
Read more arrow_forwardNCT 04482309 Brief Summary This is an open-label, multi-center, multi-cohort, Phase 2…
Read more arrow_forward